Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer

British Journal of Surgery

Volumn 92, Issue 9, 2005, Pages 1103-1109

  Kodera, Y ^a,f   Sasako, M ^b   Yamamoto, S ^c   Sano, T ^b   Nashimoto, A ^d   Kurita, A ^e  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d NIIGATA CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL ABSCESS; ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; BODY MASS; CANCER STAGING; CHOLECYSTITIS; CONTROLLED STUDY; DIARRHEA; FEMALE; GRAFT OCCLUSION; HEART FAILURE; HUMAN; ILEUS; INTESTINE OBSTRUCTION; LUNG EMBOLISM; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OPERATION DURATION; PANCREAS FISTULA; PANCREAS RESECTION; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RISK FACTOR; SEPSIS; STOMACH CANCER; SURGICAL MORTALITY; URINARY TRACT INFECTION; ANALYSIS OF VARIANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GASTRECTOMY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH TUMOR;

ADULT; AGED; ANALYSIS OF VARIANCE; FEMALE; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; PANCREATECTOMY; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS;

EID: 24744448481     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4979     Document Type: Article

References (28)

1. Ekstrom AM, Hansson LE, Signorello LB, Lindgren A, Bergstrom R, Nyren O. Decreasing incidence of both major histologie subtypes of gastric carcinoma - a population-based study in Sweden. Br J Cancer 2000; 83: 391-396.
2. Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1997; 80: 2333-2341.
3. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29.
4. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657.
5. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21: 54-59.
6. McNeer G, Lawrence W Jr, Ortega LG, Sunderland DA. Early results of extended total gastrectomy for cancer. Cancer 1956; 9: 1153-1159.
7. Jinnai D. Evaluation of extended radical operation for gastric cancer, with regard to lymph node metastasis and follow-up results. Jpn J Cancer Res 1968; 3: 225-231.
8. Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg 2002; 195: 855-864.
9. Baba M, Hokita S, Natsugoe S, Miyazono T, Shimada M, Nakano S et al. Paraaortic lymphadenectomy in patients with advanced carcinoma of the upper-third of the stomach. Hepatogastroenterology 2000; 47: 893-896.
10. Kunisaki C, Shimada H, Yamaoka H, Takahashi M, Ookubo K, Akiyama H et al. Indications for paraaortic lymph node dissection in gastric cancer patients with paraaortic lymph node involvement. Hepatogastroenterology 2000; 47: 586-589.
11. Isozaki H, Okajima K, Fujii K, Nomura E, Izumi M, Mabuchi H et al. Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterology 1999; 46: 549-554.
12. Maeta M, Yamashiro H, Saito H, Katano K, Kondo A, Tsujitani S et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery 1999; 125: 325-331.
13. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial (JCOG9501) comparing D2 and extended para-aortic lymphadenectomy. Japan Clinical Oncology Group Study 9501. J Clin Oncol 2004; 22: 2767-2773.
14. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998; 1: 10-24.
15. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530.
16. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJH. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 1999; 340: 908-914.
17. Hartgrink HH, van de Velde CJH, Putter H, Bonenkamp JJ, Klein-Kranenbarg E, Songun K et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 2004; 22: 2069-2077.
18. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H, Okajima K. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995; 19: 532-536.
19. Furukawa H. Hiratsuka M, Ishikawa O, Ikeda M, Imamura H, Masutani S et al. Total gastrectomy with dissection of lymph nodes along the splenic artery: a pancreas-preserving method. Ann Surg Oncol 2000; 7: 669-673.
20. Degiuli M, Sasako M, Ponti A, Soldati T, Danese F, Calvo F. Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol 1998; 16: 1490-1493.
21. Sasako M for the Dutch Gastric Cancer Study Group. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg 1997; 84: 1567-1571.
22. Sano T, Yamamoto S, Sasako M for the Gastric Cancer Surgical Study Group of Japan Clinical Oncology Group. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan Clinical Oncology Group study JCOG O110-MF. Jpn J Clin Oncol 2002; 32: 363-364.
23. Bonenkamp JJ, van de Velde CJ, Kampschoer GH, Hermans J, Hermanek P, Bemelmans M et al. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World J Surg 1993; 71: 410-415.
24. Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K et al. Obesity and outcome of distal gastrectomy with D2 lymphadenectomy for carcinoma. Hepatogastroenterology 2004; 51: 1225-1228.
25. Dhar DK, Kubota H, Tachibana M, Koto T, Tabara H, Masunaga R et al. Body mass index determines the success of lymph node dissection and predicts the outcome of gastric carcinoma patients. Oncology 2000; 59: 18-23.
26. Inagawa S, Adachi S, Oda T, Kawamoto T, Koike N, Fukao K. Effect of fat volume on postoperative complications and survival rate after D2 dissection for gastric cancer. Gastric Cancer 2000; 3: 141-144.
27. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1963 to 1991. JAMA 1994; 272: 205-211.
28. Sue-Ling HM, Johnston D, Martin IG, Dixon MF, Lansdown MR, McMahon MJ et al. Gastric cancer: a curable disease in Britain. BMJ 1993; 307: 591-596.